The 1995 pill scare revisited: anatomy of a non-epidemic

被引:49
作者
Spitzer, WO
机构
[1] McGill Univ, Montreal, PQ H3A 2T5, Canada
[2] Stanford Univ, Palo Alto, CA 94304 USA
关键词
cardiovascular events; epidemiology; oral contraceptives; venous thromboembolism;
D O I
10.1093/humrep/12.11.2347
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Two years after the October 1995 pill scare that received worldwide attention, this synthesis of evidence goes back to the earliest research on risks of first generation oral contraceptives (OCs). It also covers epidemiological data published since, emphasising the 1995-1996 findings. Late breaking data are also examined. The key issue: are there differences in the risk profiles of second and third generation OCs. The ultimate question is: did any epidemics of venous thromboembolism (VTE) occur? This synthesis of evidence leads to the following conclusions and observations: (i) all OCs on the market are becoming progressively safer; (ii) relative risks of about 2 for VTE, even if real, are clinically unimportant and of no public health significance; (iii) the weak odds ratios contrasting third and second generation OCs, ranging from 1.5 to 2.3 in the 1995-1996 studies are more likely explained by bias than by a causal relationship; (iv) incidences of VTE among users of any OC have been declining over the past three decades; (v) absolute rates of VTE for third generation OC users reported in 1995-1996 are lower than those for users of second generation OCs in 1988 and 1991; (vi) there is no difference in risk of VTE between first starters on second generation OCs versus first starters on third generation OCs; (vii) users of third generation OCs are at much lower risk of acute myocardial infarction than users of second generation OCs; (viii) among users of any OC, the occurrence rates of stroke are low, they are declining, and no differences between second and third generation OCs are apparent; (ix)2 years after the pill scare there are no epidemics of VTE; (x) there have been excessive rates of therapeutic abortions in some countries; and (xi) the benefit-risk ratio is favourable for users of any OC.
引用
收藏
页码:2347 / 2357
页数:11
相关论文
共 83 条
[1]  
[Anonymous], 1967, J R Coll Gen Pract, V13, P267
[2]   COMPARISON OF 2 TRIPHASIC CONTRACEPTIVES WITH DIFFERENT PROGESTOGENS - EFFECTS ON METABOLISM AND COAGULATION PROTEINS [J].
BALL, MJ ;
ASHWELL, E ;
JACKSON, M ;
GILLMER, MDG .
CONTRACEPTION, 1990, 41 (04) :363-376
[3]   ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN [J].
BLOEMENKAMP, KWM ;
ROSENDAAL, FR ;
HELMERHORST, FM ;
BULLER, HR ;
VANDENBROUCKE, JP .
LANCET, 1995, 346 (8990) :1593-1596
[4]   REMOVAL OF ACUTE CORONARY THROMBUS WITH FIBRINOLYSIN-IN VIVO EXPERIMENT - A PRELIMINARY REPORT ON USE OF FIBRINOLYTIC AGENTS IN TREATMENT OF ACUTE THROMBOSIS [J].
BOLTON, HE ;
MAZEL, MS ;
RIERA, R ;
TAPIA, FA ;
CABRAL, H .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1961, 175 (04) :307-&
[5]  
Bonnar J, 1987, Int J Fertil, V32 Suppl, P21
[6]  
BOTTIGER LE, 1971, ACTA MED SCAND, V190, P455
[7]  
*BRIT NAT FORM, 1988, BRIT NAT FORM, P269
[8]   A COMPARISON OF THE EFFECTS OF 2 TRIPHASIC ORAL-CONTRACEPTIVES ON HEMOSTASIS [J].
COHEN, H ;
MACKIE, IJ ;
WALSHE, K ;
GILLMER, MDG ;
MACHIN, SJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 69 (02) :259-263
[9]  
Cohen J, 1996, HUM REPROD, V11, P689
[10]  
COLLET JP, 1994, PHARMACOEPIDEM DR S, P612